AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alonso, R.
Right arrow Articles by Courvalin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alonso, R.
Right arrow Articles by Courvalin, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2002, p. 3686-3687, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3686-3687.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

parC Mutation Conferring Ciprofloxacin Resistance in Streptococcus pyogenes BM4513


   LETTER
Top
 Letter
References
 
Streptococcus pyogenes is responsible for high rates of morbidity due to an increase in invasive group A streptococcal infections and bacteremia worldwide during the last decade (2, 3). The goal of this study was to elucidate the mechanism of fluoroquinolone resistance in S. pyogenes BM4513 isolated in 2000 from the pharynx of a patient at the Hospital de Basurto, Bilbao, Spain.

In gram-positive cocci, fluoroquinolone resistance has been associated with mutational alterations in both targets, DNA gyrase and topoisomerase IV, or with active efflux of the drugs (4). Low-level fluoroquinolone resistance usually results from mutations in the quinolone resistance-determining regions of either the ParC subunit of topoisomerase IV or the GyrA subunit of the DNA gyrase, depending on the fluoroquinolone used as selector. For example, in Streptococcus pneumoniae, ciprofloxacin, levofloxacin, norfloxacin, pefloxacin, and trovafloxacin have ParC or ParE as the primary target, whereas GyrA is the preferred target of clinafloxacin, gatifloxacin, gemifloxacin, moxifloxacin, and sparfloxacin (5, 7, 8, 10).

The MICs of antibiotics were determined by the microdilution method according to the NCCLS guidelines (Table 1). The ciprofloxacin MICs remained unchanged in the presence of reserpine (10 µg/ml).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Susceptibility of streptococci to selected fluoroquinolones and substitution in the ParC subunit

 
A 614-bp PCR fragment internal to gyrA and a 520-bp amplified fragment of parC obtained with specific primers (11) and total DNA of BM4513 as a template were sequenced directly on both strands with an automated sequencer (CEQ 2000 DNA Analysis System; Beckman Coulter).

As compared to the susceptible strains CIP5641T and ATCC 700294 (GenBank accession number AF220946), S. pyogenes BM4513 had a base pair change (TCC/GCC) in the parC gene at position 366 that resulted in amino acid substitution Ser79Ala (S. pyogenes coordinates). No mutations in the quinolone resistance-determining region of gyrA were detected.

To determine the contribution of the mutation to resistance in S. pyogenes BM4513, amplified DNA (1 µg) containing the mutation was transformed into S. pneumoniae CP1000 (6) with selection on ciprofloxacin (2 µg/ml). The TCC/GCC (Ser79Ala) mutation was amplified as part of a 792-bp PCR product obtained with the forward primer (11) and the reverse primer 5'-GTTAACTTCATAAGGAATCTCAGT-3' (nucleotides 769 to 792, S. pyogenes coordinates). The corresponding PCR product was also amplified from DNA of susceptible strain CIP5641T. Only the transformation using amplified DNA from BM4513 yielded resistant colonies with a frequency of 1.1 x 10-6 versus <10-9 for the control. The DNA of two transformants amplified with the same primers was sequenced and found to contain the GCC mutation at codon 79. The MICs of fluoroquinolones for one of the transformants, BM4514, were determined and found to be identical to those against S. pyogenes BM4513 (Table 1). The corresponding mutation in the parC gene has been shown to confer low-level fluoroquinolone resistance (MICs, 4 to 8 µg/ml) in S. pyogenes mutants obtained in vitro (9) and in S. pneumoniae (1).

This study indicates that, in S. pyogenes BM4513, ciprofloxacin resistance was due to the Ser79Ala substitution in the ParC subunit of topoisomerase IV and that massive use of fluoroquinolones can select resistant mutants in nontarget bacterial species.


   ACKNOWLEDGMENTS
 
We thank Ramón Cisterna for providing S. pyogenes BM4513.

R. Alonso was the recipient of a postdoctoral grant from the Basque government. This work was supported in part by a Bristol-Myers Squibb Unrestricted Biomedical Research Grant in Infectious Diseases.


   REFERENCES
Top
 Letter
 References
 

  1. Bast, D. J., D. E. Low, C. L. Duncan, L. Kilburn, L. A. Mandell, R. J. Davidson, and J. C. de Azavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44:3049-3054.[Abstract/Free Full Text]
  2. Cunningham, M. W. 2000. Pathogenesis of group A streptococcal infections. Clin. Microbiol. Rev. 13:470-511.[Abstract/Free Full Text]
  3. Efstratiou, A. 2000. Group A streptococci in the 1990s. J. Antimicrob. Chemother. 45(Suppl.):3-12.[Abstract]
  4. Hooper, D. C. 1999. Mechanisms of fluoroquinolone resistance. Drug Resist. Updates 2:38-55.[CrossRef][Medline]
  5. Li, X., X. Zhao, and K. Drlica. 2002. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob. Agents Chemother. 46:522-524.[Abstract/Free Full Text]
  6. Morrison, D. A., M.-C. Trombe, M. K. Hayden, G. A. Waszak, and J.-D. Chen. 1984. Isolation of transformation-deficient Streptococcus pneumoniae mutants defective in control of competence, using insertion-duplication mutagenesis with the erythromycin resistance determinant of pAMß1. J. Bacteriol. 159:870-876.[Abstract/Free Full Text]
  7. Muñoz, R., and A. G. De La Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.[Abstract]
  8. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.[Abstract]
  9. Schmitz, F.-J., M. Boos, S. Mayer, K. Köhrer, and S. Scheuring. 2002. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones. Antimicrob. Agents Chemother. 46:934-935.[Free Full Text]
  10. Weigel, L. M., G. J. Anderson, R. R. Facklam, and, F. C. Tenover. 2001.Genetic analysis of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:3517-3523.[Abstract/Free Full Text]
  11. Yan, S. S., M. L. Fox, S. M. Holland, F. Stock, V. J. Gill, and, D. P. Fedorko. 2000. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob. Agents Chemother. 44:3196-3198.[Abstract/Free Full Text]
Rodrigo Alonso
Marc Galimand
Patrice Courvalin*
Unité des Agents Antibactériens
Institut Pasteur
25 rue Dr. Roux
75724 Paris Cedex 15, France

* Phone: (33) 1 45 68 83 20
Fax: (33) 1 45 68 83 19
E-mail: pcourval{at}pasteur.fr.

Antimicrobial Agents and Chemotherapy, November 2002, p. 3686-3687, Vol. 46, No. 11
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.11.3686-3687.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alonso, R.
Right arrow Articles by Courvalin, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alonso, R.
Right arrow Articles by Courvalin, P.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS